Topical PRK 124 (0.125%) lotion for improving the signs and symptoms of rosacea

Journal of Drugs in Dermatology

Volumn 8, Issue 5, 2009, Pages 459-462

  Ortiz, Arisa ^a   Elkeeb, Laila ^a   Truitt, Anne ^a   Hindiyeh, Rasha ^a   Aquino, Lisa ^a   Tran, Minh ^a   Weinstein, Gerald ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI ACNE AGENT; PRK 124; PYRATINE XR; UNCLASSIFIED DRUG; CYTOKININ; DERMATOLOGICAL AGENT; PYRATINE 6;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; FEMALE; HUMAN; MALE; PAPULE; PHYSICIAN; ROSACEA; SKIN BURNING SENSATION; SKIN FUNCTION; SKIN IRRITATION; TELANGIECTASIA; TREATMENT OUTCOME; WATER LOSS; CLINICAL TRIAL; MIDDLE AGED; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; AGED; CYTOKININS; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; ROSACEA;

EID: 67649862085     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584-587.
2. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327-341. (Pubitemid 39178655)
3. Bikowski JB, Goldman MP. Rosacea: Where are we now? J Drugs Dermatol. 2004;3(3):251-261.
4. Van Zuuren EJ, Gupta AK, Gover MD, et al. Systematic review of rosacea treatments. J Am Acad Dermatol. 2007;56(1):107-115. (Pubitemid 44969302)
5. Draelos ZD. Clinical situations conducive to proactive barrier enhancement. Cutis. 2002;70:(6 Suppl)17-20.
6. McCullough JL, Garcia RL, Reece B. A clinical study of topical Pyratine 6 for improving the appearance of photodamaged skin. J Drugs Dermatol. 2008;7(2):131-135.